We remain confident that our investigational #FGF21 analog has the potential to be a best-in-class therapeutic for patients with #MASH and #SHTG based on completed studies. Did you know that FGF21 is an endogenous hormone that functions as a master metabolic regulator that has the potential to address underlying metabolic issues that drive liver and #CardioMetabolic diseases? The science speaks for itself -- learn more about our FGF21 analog’s mechanism of action: https://lnkd.in/gCZYq9u
89bio
Biotechnology Research
San Francisco, CA 9,722 followers
Developing and commercializing innovative therapies for the treatment of liver and cardio-metabolic diseases
About us
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Recent Phase 1b/2a data show BIO89-100 demonstrated a favorable safety and tolerability profile and robust reductions in liver fat and key lipid markers when dosed weekly or once every two weeks in patients with NASH. BIO89-100 is currently in a Phase 2 trial for the treatment of SHTG. 89bio is headquartered in San Francisco with operations in Herzliya, Israel. Our culture is best described by our values: • Always putting the patient first • Operating with the highest integrity and ethical standards at all times • Being authentic in all our transactions • Acting as a team – collaborating, respecting and caring for one another • Being entrepreneurial and passionate in our tasks • Being scientific and rational in our thought process and decision-making
- Website
-
http://www.89bio.com
External link for 89bio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- San Francisco, CA
- Type
- Public Company
- Founded
- 2018
- Specialties
- Biopharmaceutical
Locations
-
Primary
San Francisco, CA, US
Employees at 89bio
Updates
-
When you're a company focused on redefining what's possible for patients with #CardioMetabolic Diseases, it's essential to pause and recalibrate. Earlier this month, 89bio employees from around the world gathered in our San Francisco office for our quarterly All Company Week. Throughout the week, we collaborated on new ideas, reflected on old ones, and recommitted to our mission of developing therapies that make a meaningful difference for patients. We've come a long way, and we're excited about how far we can go. At our company, we’re empowered to show up as our full authentic selves - that's the #89way. #Innovation #WorkCulture
Today marks the close of 89bio’s Q2 All Company Week, a cherished time when our team flies into the Company’s San Francisco office from all over the globe to connect, develop and celebrate our accomplishments. Nothing quite compares to the magic of experiences where people feel seen, heard and valued. Many thanks to HR’s dream team who made this memorable experience possible: Trisha Colton, Nicholas Gignac, Richard Philippides of 14 PEAKS TALENT, LLC, Kelly Hoffman-Davis of The Graphic Works & Dr. Marc Camras! Happy Pride to all! ✨🌈 🪩#89bio #the89way #culturematters
-
In May, Dr. Arun J. Sanyal (Virginia Commonwealth University) joined 89bio to discuss the unmet need and current treatment landscape for advanced metabolic dysfunction-associated steatohepatitis (#MASH) patients with fibrosis and compensated cirrhosis. During his presentation, Dr. Sanyal discusses the importance of treatment options that have anti-fibrotic effects which is showcased in this clip. For more information and latest research on the potent anti-fibrotic effects of our investigational FGF21 analog, listen to the full presentation: https://lnkd.in/gMyuxHZW
-
Exciting growth is happening at 89bio! We're currently seeking dynamic individuals who pursue excellence to benefit patients, embody an entrepreneurial mindset, and are eager to be driven by science as we continue to innovate for #CardioMetabolic diseases. Discover what makes the 89bio way unique and see if you’d be a good candidate for one of our open roles: https://lnkd.in/gbijsSjq #the89Way #BioPharma #Recruitment #JobOpening #NewJobs
-
-
As we enter the second half of 2024, we are more steadfast than ever in our commitment to delivering innovative therapies for liver disease patients. Last month, we initiated our second Phase 3 clinical trial in #MASH in our ENLIGHTEN program. These two clinical trials, along with our ongoing Phase 3 trial in #SHTG, will evaluate the safety and efficacy of our investigational #FGF21 analog and bring us one step closer to delivering this potential best-in-class therapy to patients. Learn more about the recent advancements we’ve made in our clinical development pipeline: https://lnkd.in/guaY8Zz #MASH #Innovation #SHTG
-
Our CEO, Rohan Palekar, and Dr. Arun Sanyal from Virginia Commonwealth University recently joined Simon Wentworth on The Pharma Letter Podcast to discuss the #MASH landscape and what’s next for 89bio and our lead therapeutic candidate. Tune in to the podcast episode to hear their discussion!
The Pharma Letter Podcast — Episode 28 — Breakthroughs in MASH, with 89bio CEO https://lnkd.in/dKtCiHpF
-
Yesterday was Global #FattyLiverDay! At 89bio, we remain dedicated to advancing research and developing our innovative treatment for patients with #MASH, a severe form of fatty liver disease. It is important to continue raising awareness of this chronic, progressive disease which fat accumulates in the liver, ultimately leading to fibrosis (or scarring). MASH is often a silent disease with few or no symptoms, making it particularly dangerous as it can lead to more severe liver damage, including cirrhosis and liver cancer if left unchecked. Learn more about MASH, and why early screening is important from Global Liver Institute: https://lnkd.in/gSCgcPJh
-
In case you missed it, we recently presented our latest research in #MASH at the 2024 #EASLCongress. This year’s congress was a great success, filled with collaborative discussions and innovative ideas aimed at improving patient outcomes in liver diseases. Thank you to everyone who listened in on our poster and oral presentations and engaged in meaningful conversations with our team. For more information, read our poster: https://lnkd.in/ge-cQQk5 #ICYMI #MASH
-
-
#EASLCongress begins tomorrow in Milan, where we will take the stage to present our latest findings in #MASH research. We’re excited to take part in this opportunity and discuss the latest innovations that may improve the lives of patients with liver diseases. Learn more: https://lnkd.in/gikxitnV #Innovation #EASLCongress
-
-
We’re excited to be presenting data from our Phase 2b ENLIVEN study in #MASH at the upcoming European Association for the Study of the Liver 2024 Congress. To learn more about our data presentations, read our release: https://lnkd.in/gikxitnV #Innovation #EASLCongress
-